Safety review record^↗↗Safety records^↗↗

MOTS-c^↗

Related names in cited records: MOTS-C^↗

A mitochondrial-derived peptide represented in FDA compounding-risk and advisory-committee records.^↗↗↗

Citation markers ↗ open the public records supporting the adjacent statements.

Profile update · July 29, 2026

We added FDA's dedicated briefing and advisory-committee meeting record, while preserving the pending and nonbinding nature of the review. ²³

This version supersedes public version 1.

Evidence summary

What the cited records say

FDA presented MOTS-c briefing material at its July 2026 pharmacy-compounding advisory-committee meeting. Committee recommendations are nonbinding, and FDA says its final determination will follow completion of the committee process and relevant reviews.^↗↗

This is a source summary, not a medical recommendation. Status may differ by jurisdiction and product.

Cited context

Related records

Organizations named in cited records

U.S. Food and Drug Administration^↗↗↗

Dated source history

Updates connected to this profile

July 24, 2026
Regulatory
FDA committee met on seven peptide-related groups of bulk drug substances^↗
FDA convened its Pharmacy Compounding Advisory Committee on July 23-24, 2026, to discuss free-base and acetate bulk drug substances across seven peptide-related groups.^↗